Semaglutide vs tirzepatide vs retatrutide: 3-way

Three drugs sit at the center of the obesity-medicine conversation in 2026, and they are not equals. Semaglutide and tirzepatide are FDA-approved and sitting in pharmacy fridges right now, while retatrutide is still an investigational drug that has not been approved by any regulator. This guide walks through how each one works, what the actual trial data shows, where the evidence is strong and where it is thin, and who each drug fits best.

The short version: where each drug stands in 2026

Before going deep, it helps to know the lay of the land. Two of these three are real prescriptions. One is not yet a prescription at all.

Semaglutide (brand names Ozempic for diabetes, Wegovy for obesity) is a single-target GLP-1 receptor agonist. It is approved, widely used, and has the longest safety record of the three.
Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) hits two targets, GIP and GLP-1. It is approved and, in head-to-head testing, beats semaglutide on weight loss.
Retatrutide is an investigational triple agonist that hits three targets, GIP, GLP-1, and glucagon. It has produced the largest weight-loss numbers ever reported for a drug, but it is not approved and will not be in pharmacies until late 2027 at the earliest. Anything sold as "retatrutide" today is unregulated.

That last point matters most. If you read nothing else, read this: retatrutide is not a legal prescription medication in 2026. The data is exciting. The drug is not available.

How the three drugs actually work

All three belong to a family called incretin therapies. Incretins are gut hormones your body releases after you eat. They tell your pancreas to make insulin, slow how fast your stomach empties, and signal your brain that you are full. The drugs in this class are lab-made versions of these hormones, tuned to last about a week per dose.

The difference between the three comes down to how many hormone receptors each one activates.

Semaglutide: one receptor

Semaglutide is a GLP-1 receptor agonist. It mimics one hormone, glucagon-like peptide-1. That single action lowers blood sugar, slows stomach emptying, and reduces appetite. It is the simplest of the three mechanisms, and being first to market gave it the deepest safety track record.

Tirzepatide: two receptors

Tirzepatide adds a second target. It activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. The thinking is that GIP and GLP-1 together improve how the body handles sugar and fat better than GLP-1 alone, and may ease the nausea that comes with strong GLP-1 activity. The clinical results back up the idea that two targets beat one.

Retatrutide: three receptors

Retatrutide goes a step further and adds glucagon to the mix. It is a GIP, GLP-1, and glucagon receptor agonist. Glucagon sounds counterintuitive here because the hormone raises blood sugar. But glucagon also increases energy expenditure, meaning your body burns more calories at rest, and it helps the liver shed fat. The bet behind retatrutide is that adding glucagon turns up calorie burn on top of the appetite suppression you already get from GLP-1 and GIP. Early data suggests the bet is paying off, with the important caveat that glucagon's effect on heart rate and blood sugar needs careful long-term study.

Head-to-head weight loss: what the trials show

This is where the differences become concrete. The numbers below come from the registrational trials for each drug. One caution up front: comparing across separate trials is unreliable because trial populations, durations, and designs differ. The only fully fair comparison in this whole field is SURMOUNT-5, which pitted tirzepatide directly against semaglutide in the same study.

Drug	Key trial	Population	Top dose	Avg. weight loss	Duration
Semaglutide 2.4 mg	STEP 1	Obesity, no diabetes	2.4 mg/week	14.9%	68 weeks
Tirzepatide	SURMOUNT-1	Obesity, no diabetes	15 mg/week	~20.9%	72 weeks
Retatrutide	Phase 2 (Jastreboff)	Obesity, no diabetes	12 mg/week	24.2%	48 weeks
Tirzepatide vs semaglutide	SURMOUNT-5 (direct)	Obesity, no diabetes	10–15 mg vs 1.7–2.4 mg	20.2% vs 13.7%	72 weeks

Semaglutide's number

In the STEP 1 trial, adults with obesity who took weekly 2.4 mg semaglutide lost an average of 14.9% of their body weight over 68 weeks, compared with 2.4% on placebo. About 86% of people lost at least 5% of their weight. This was a landmark result when it published in 2021, because no GLP-1 drug had reached that level before. (STEP 1, Wilding et al., NEJM 2021)

Tirzepatide's number

In SURMOUNT-1, adults with obesity on the 15 mg dose lost roughly 20.9% of their body weight over 72 weeks. That pushed the ceiling higher and made tirzepatide the most effective approved obesity drug. (SURMOUNT-1, Jastreboff et al., NEJM 2022)

The only fair fight: SURMOUNT-5

SURMOUNT-5 is the trial that actually matters for a head-to-head, because it tested both drugs in the same people under the same conditions. Over 72 weeks, tirzepatide produced 20.2% average weight loss versus 13.7% for semaglutide. About 32% of the tirzepatide group lost at least 25% of their body weight, versus 16% on semaglutide. The trial was open-label, meaning patients and doctors knew which drug they got, which is a real limitation, but the size of the gap is hard to explain away. (SURMOUNT-5, Aronne et al., NEJM 2025)

Retatrutide's number, and why to read it carefully

Retatrutide's Phase 2 trial reported 24.2% average weight loss at the 12 mg dose over 48 weeks, the largest figure published for any obesity drug at that point. (Retatrutide Phase 2, Jastreboff et al., NEJM 2023)

In 2025 and 2026, Eli Lilly's Phase 3 TRIUMPH program reported topline results in the 25% to 28% range at the higher doses, with the highest numbers coming from people who stayed on treatment longest. The TRIUMPH trials are real and registered, and the design has been published in a peer-reviewed journal. (TRIUMPH design, Lilly investigators, Diabetes Obes Metab 2026)

Here is the honest grading. As of mid-2026, the full Phase 3 efficacy and safety results for retatrutide had been announced mainly through company press releases and conference presentations, not yet through complete peer-reviewed publications for every trial. Press-release numbers tend to be the best-case framing. They are not fabricated, but they are selected. Until the full TRIUMPH papers are out and independently reviewed, treat the 28% figure as promising rather than settled. And remember the comparison across trials is not apples to apples. Retatrutide's Phase 2 ran 48 weeks; tirzepatide's SURMOUNT-1 ran 72. Longer trials usually show more weight loss, so part of any gap could shrink or grow once the timelines match.

Approval status: the part people skip

It is easy to lump these three together because they share a mechanism family. Legally and practically, they are not in the same place.

Drug	Obesity brand	FDA status (mid-2026)	How you can get it
Semaglutide	Wegovy	Approved	Prescription
Tirzepatide	Zepbound	Approved	Prescription
Retatrutide	None yet	Investigational, not approved	Clinical trial only

Tirzepatide for obesity (Zepbound) carries an FDA-approved label. (FDA Zepbound prescribing information) Semaglutide products for diabetes and weight loss are also FDA-regulated, and the agency maintains active safety information for the molecule. (FDA semaglutide drug safety information)

Retatrutide has none of this. Eli Lilly is expected to file for approval in late 2026, with a realistic launch in 2027 or 2028. So if a website, clinic, or "research peptide" seller offers you retatrutide today, you are not buying an approved drug. You are buying an unregulated product with no guaranteed identity, purity, or dose. People do this, and the gray market is large, but it sits outside any safety net. For more on the line between regulated and gray-market products, see our guide to compounded versus brand-name GLP-1 safety, cost, and legality.

Dosing and how you take each drug

All three are weekly injections you give yourself under the skin, usually in the belly, thigh, or upper arm. And all three follow the same basic rule: start low, go slow. Jumping straight to a high dose is how you end up nauseated and miserable, so doctors step the dose up over weeks or months to let your gut adjust.

Feature	Semaglutide (Wegovy)	Tirzepatide (Zepbound)	Retatrutide
Route	Weekly injection	Weekly injection	Weekly injection
Starting dose	0.25 mg	2.5 mg	2 mg (trial)
Top dose	2.4 mg	15 mg	12 mg (trial)
Time to reach top dose	~16+ weeks	~20+ weeks	~5+ months (trial)
Device	Prefilled pen	Prefilled pen or vial	Trial-supplied only

A few practical points worth knowing:

The slow ramp-up is not optional. With semaglutide you usually spend a month at each dose level before moving up. Tirzepatide and retatrutide use the same staircase approach. Skipping steps trades a little speed for a lot of nausea, and most people who quit do so during a too-fast escalation.
Missing a dose has rules. With the weekly drugs, a missed dose can often be taken within a few days, but if you go too long you may need to restart at a lower dose. Always follow your prescriber's guidance rather than guessing.
Retatrutide dosing comes only from trials. The numbers above reflect the doses used in the TRIUMPH studies. There is no FDA-approved label telling a pharmacist how to dispense it, because it has no label. The doses sold on the gray market are not standardized and may not match anything tested in a trial. For a closer look at how the trials structured retatrutide doses, see what doses the retatrutide trials actually used.

The shared takeaway: these are not pills you swap casually. Dose changes belong with a prescriber, and for retatrutide there is no legitimate prescriber-to-pharmacy path at all in 2026.

What it costs and how you get it

Effectiveness only matters if you can actually obtain and afford the drug. This is another place where the three split apart hard.

Semaglutide and tirzepatide both carry high list prices, often more than a thousand dollars a month before insurance or discounts. Coverage is uneven. Some plans pay for these drugs for obesity, many do not, and the ones that do often require prior authorization and proof you have tried other approaches. Both manufacturers run savings programs and self-pay vial options that can bring the cash price down, and the gap between list price and what people actually pay is wide.

Retatrutide has no price at all because it has no commercial product. You cannot buy it legally. The only no-cost way to access it is to qualify for and enroll in a clinical trial, where the drug is provided as part of the study.

The pricing landscape changes fast, so it pays to check current numbers before committing. Our GLP-1 cost and access guide tracks list prices, coupon programs, and coverage rules in detail. A few habits help across the board: ask your prescriber about manufacturer savings cards, check whether a vial option is cheaper than the pen, and confirm your insurance's specific obesity-coverage rules before you start, not after.

One more honest warning on cost: the price gap is exactly what fuels the retatrutide gray market. People see a drug that may outperform what is approved, can't get it, and turn to unregulated sellers. That demand is understandable. It is also where the real danger lives, because an unregulated injectable carries risks that have nothing to do with the molecule itself and everything to do with what's actually in the vial.

Beyond weight: the other health effects

Weight loss is the headline, but these drugs do more, and the non-weight data is part of how you choose.

Cardiovascular outcomes

Semaglutide has the strongest hard-outcome data here. The SELECT trial showed that in people with obesity and existing cardiovascular disease but no diabetes, semaglutide cut the risk of heart attack, stroke, or cardiovascular death by about 20% over roughly three years. That is a genuine outcomes trial, not a surrogate marker, and it is the kind of evidence that takes years to produce. (SELECT, Lincoff et al., NEJM 2023)

Tirzepatide's dedicated cardiovascular-outcomes trial has been read out more recently, and it does not yet carry the same depth of long-term, peer-reviewed outcome history that semaglutide built through SELECT. Retatrutide has no completed cardiovascular-outcomes trial at all. This is one place where the newest, most powerful weight-loss drug has the least proof of heart benefit. Bigger weight loss does not automatically mean bigger heart protection until a trial shows it.

Blood sugar and diabetes

All three lower blood sugar. In type 2 diabetes, tirzepatide generally produces larger drops in A1C than semaglutide, and retatrutide's diabetes trials show strong control too. If diabetes is your main concern, the dual and triple agonists have an edge on glucose, though semaglutide remains a solid, well-studied choice. For a deeper look at the diabetes-specific data, see tirzepatide vs semaglutide for diabetes.

Liver, kidney, and other signals

Retatrutide's glucagon component appears especially active in the liver, and early studies suggest meaningful reductions in liver fat. Tirzepatide has its own promising liver-disease data. These are real signals, but most are still early or based on imaging and lab markers rather than long-term outcomes. Treat them as encouraging leads, not finished stories.

Safety and side effects

The side-effect profile is similar across all three because they share a mechanism. Most problems are gastrointestinal and most are worst during dose escalation.

Side effect	Semaglutide	Tirzepatide	Retatrutide
Nausea	Common	Common	Common
Vomiting / diarrhea	Common	Common	Common
Constipation	Common	Common	Common
Appetite loss	Expected	Expected	Expected
Heart rate increase	Mild	Mild	Notable (glucagon effect)
Gallbladder issues	Possible	Possible	Possible
Muscle loss with fat loss	Yes	Yes	Yes, possibly more

A few honest notes on safety:

Gut side effects are the main reason people quit. Nausea, vomiting, and diarrhea hit hardest in the first weeks and usually fade. Slow dose increases and smaller meals help. Our guide on managing GLP-1 nausea covers practical steps.
Retatrutide raises heart rate more than the other two, a predictable result of the glucagon target. Trials are watching this closely. Whether it matters for long-term heart health is still an open question, which is exactly why the missing cardiovascular-outcomes data is a real gap.
Muscle loss comes with all fast weight loss, drug-driven or not. The bigger the weight loss, the more attention muscle preservation needs through protein and resistance training. See preventing muscle loss on GLP-1 medications.
Rare but serious risks across the class include pancreatitis and gallbladder disease, and these drugs carry a boxed warning about thyroid C-cell tumors based on rodent studies, which is why they are not used in people with a personal or family history of medullary thyroid cancer.

The longer a drug has been on the market, the more we know about its rare risks. By that measure semaglutide leads, tirzepatide follows, and retatrutide trails because it simply has not been used long enough in enough people to surface uncommon problems.

Who each drug is for

There is no single best drug. The right choice depends on your goals, your other conditions, and what you can actually get.

Semaglutide makes sense if you have heart disease and want a drug with proven cardiovascular benefit, you value the longest safety record, or you want moderate weight loss with a well-mapped side-effect profile. It is the conservative, well-proven pick.

Tirzepatide makes sense if your priority is maximum approved weight loss today, you have type 2 diabetes and want strong glucose control, or semaglutide has not given you the results you wanted. In the only direct comparison, it won on weight. For people considering a switch, our guide on moving from semaglutide to tirzepatide walks through the practical steps.

Retatrutide is for people enrolling in a clinical trial, or people watching the pipeline for a future option. It is not a choice you can make at a pharmacy in 2026. If the Phase 3 data holds up through full publication and approval, it may become the most powerful option in the class. That day has not arrived.

A reasonable way to think about it: start with what is approved and matched to your health needs. Keep an eye on retatrutide, but do not chase the gray market to get it early.

The bottom line

Semaglutide is the proven veteran with the best heart-outcome data. Tirzepatide is the current weight-loss champion among approved drugs, with a clean head-to-head win over semaglutide. Retatrutide is the most powerful number on paper and the least available drug in practice, with the thinnest long-term safety record and no approval. The gap between the three is partly about effectiveness and partly about how much we actually know. On that second measure, the order flips: the oldest drug is the best understood, and the newest is the biggest unknown.

Frequently Asked Questions

Is retatrutide available by prescription in 2026?

No. Retatrutide is investigational and not approved by the FDA or other major regulators as of mid-2026. The only legitimate way to access it is through a clinical trial. Eli Lilly is expected to file for approval in late 2026, with a possible launch in 2027 or 2028. Products sold online as retatrutide today are unregulated and not quality-controlled.

Does retatrutide really cause more weight loss than tirzepatide?

The early data suggests yes, with retatrutide reaching the mid-20s to high-20s percent range versus about 21% for tirzepatide. But these come from separate trials of different lengths, not a head-to-head study, so the comparison is not reliable. Retatrutide's Phase 2 ran 48 weeks while tirzepatide's main trial ran 72. A direct comparison would settle the question, and none has been done.

Why does retatrutide raise heart rate more?

Retatrutide activates the glucagon receptor in addition to GLP-1 and GIP. Glucagon increases energy expenditure, which helps burn calories, but it can also raise resting heart rate. Trials are monitoring this carefully. Whether the heart-rate increase carries long-term cardiovascular risk is not yet known, which is part of why retatrutide still needs more study.

Which drug is best if I have heart disease?

Semaglutide currently has the strongest evidence, based on the SELECT trial showing a roughly 20% reduction in major cardiovascular events in people with obesity and established heart disease. Tirzepatide's heart-outcome data is more recent and less mature, and retatrutide has no completed cardiovascular-outcomes trial. Always make this decision with your doctor.

Can I switch between these drugs?

Switching between approved drugs like semaglutide and tirzepatide is common and done under medical supervision, usually restarting dose escalation on the new drug to limit side effects. You cannot switch to retatrutide because it is not approved. Never switch or stack these medications on your own.

This article is for general information only and is not medical advice. GLP-1 medications are prescription drugs with real risks. Talk to a licensed healthcare provider before starting, stopping, or switching any medication.